We are live on ! Find out more
NKTR icon

Nektar Therapeutics

236 hedge funds and large institutions have $3.4B invested in Nektar Therapeutics in 2021 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 70 increasing their positions, 85 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

8% more call options, than puts

Call options by funds: $9.18M | Put options by funds: $8.48M

2.85% less ownership

Funds ownership: 96.08% → 93.23% (-2.8%)

4% less funds holding

Funds holding: 246 → 236 (-10)

18% less repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 85

28% less capital inflows, than outflows

Capital inflows: $138M | Capital outflows: $191M

32% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 34

Holders
236
Holders Change
-10
Holders Change %
-4.07%
% of All Funds
4.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
23
Increased
70
Reduced
85
Closed
34
Calls
$9.18​M
Puts
$8.48​M
Net Calls
+$701​K
Net Calls Change
-⁠$9.48​M

NKTR Hedge Fund Activity: Q1 2021 in Review

236 of the 5,709 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q1 2021, worth a combined $3.4B — up 16% from $2.93B a quarter earlier.

Sellers outnumbered buyers: 34 funds closed out of NKTR and 23 opened new positions — a net loss of 11 holders — while 85 trimmed existing stakes and 70 added.

The largest buyer was Ameriprise, adding an estimated $34.4M. The largest seller was Wellington Management Group, cutting an estimated $41.7M.

  • 236 institutional investors held Nektar Therapeutics (NKTR) as of Q1 2021, down from 246 in Q4 2020.
  • Funds reported $3.4B of Nektar Therapeutics stock for Q1 2021, up 16% quarter-over-quarter.
  • 23 funds opened new Nektar Therapeutics positions in Q1 2021 and 34 closed out, a net change of -11 holders.
  • The largest Nektar Therapeutics buyer in Q1 2021 was Ameriprise, an estimated $34.4M added.
  • The largest Nektar Therapeutics seller in Q1 2021 was Wellington Management Group, an estimated $41.7M sold.

Based on aggregated 13F filings for Q1 2021.